Andrade-Oliveira et al. demonstrated that intraperitoneal injection with SCFAs, twice individually at 30 minutes before ischemia and the moment of reperfusion, improved acute kidney injury (AKI) by decreasing inflammatory cytokines and chemokines locally and systemically though inhibiting NF-kB signaling pathway 12. This evidence concerns the gene NFKB1 and acute kidney injury.